Meme cancer stages classify the extent of the disease from Stage 0 to Stage 4 and constitute the fundamental system that determines the personalized treatment protocol. Stage 0 (DCIS) represents the earliest phase in which cancer cells have not yet spread beyond the milk ducts, while Stages 1 and 2 indicate the early stage where the tumor is confined to the breast or a limited number of axillary lymph nodes. Cases in which the disease has spread to a wider area or extensively to the lymph nodes are referred to as Stage 3 (locally advanced), whereas the spread of cancer to distant organs such as the bones, lungs, or liver is defined as Stage 4 (metastatic). According to the current AJCC criteria, this staging system analyzes not only the anatomical size of the tumor but also its biological characteristics, directly shaping the timing of surgery and the selection of medications.
Why Has Breast Cancer Staging Changed and What Is Biological Staging?
For many years, we evaluated breast cancer solely based on its size measured with a ruler and its physical spread to the lymph nodes. Of course, how many centimeters the tumor measures or whether it has spread to the armpit are still very important pieces of information. However, as we see in current medical practice and in the latest guidelines of the American Joint Committee on Cancer (AJCC), looking only at the external appearance of a tumor is not sufficient to understand how dangerous it is. In the new era called biological staging, the behavior and character of the tumor have become more important than its physical size.
In this new system, as physicians, we do not make our decisions solely based on the size of the tumor. The factors that make up the biological identity of the tumor directly affect the treatment sequence and surgical decision. For example, even if a tumor is very small, if it has biologically aggressive characteristics, drug therapy may be required before surgery. Conversely, even if it is somewhat larger, a tumor with a “well-behaved” character may be treated with direct surgery. Therefore, in the modern surgical approach, the genetic and molecular data in the patient’s pathology report are at least as decisive as the tumor size we see on imaging.
The main parameters considered in biological staging are:
- Tumor grade
- Estrogen receptor status
- Progesterone receptor status
- HER2 protein status
- Multigene panel results
What Is Stage 0 (DCIS) and What Are the Surgical Treatment Options?
Stage 0 is medically called “Ductal Carcinoma In Situ” (DCIS) and represents the earliest stage of breast cancer. The key point here is the term “in situ”; this means that cancer cells have developed within the milk ducts but have not yet broken through the duct wall to spread into the surrounding tissue, blood vessels, or lymphatic channels. In other words, at this stage, the disease theoretically has no ability to spread throughout the body. However, this does not mean the disease is insignificant, because if left untreated, these cells carry the risk of eventually developing into invasive cancer:
At this stage, the primary goal of surgical treatment is to completely remove the affected area without leaving behind any tumor cells. There are generally two main options. The first is breast-conserving surgery, namely lumpectomy. In this method, only the tumor area is removed together with a small amount of surrounding healthy tissue. The most important rule of breast-conserving surgery is that the remaining breast tissue must receive radiotherapy (radiation therapy) after the operation. Radiation therapy destroys any microscopic cells that may remain, thereby reducing the risk of recurrence in the same location.
The second option is mastectomy, which involves removing the entire breast. This method is preferred if the DCIS area is very large relative to the size of the breast, if there are multiple foci in different parts of the breast, or if the patient does not wish to receive radiation therapy. When a mastectomy is performed, radiation therapy is generally no longer necessary. Today, these operations are combined with simultaneous aesthetic reconstruction, ensuring that patients do not experience the feeling of organ loss.
The factors considered when deciding between breast-conserving surgery and mastectomy are:
- Size of the tumor
- Size of the breast
- Extent of the disease
- Patient preference
- Preference regarding radiotherapy
Is Axillary Lymph Node Biopsy Necessary in Stage 0 Patients?
One of the issues our patients fear most during breast cancer surgery is intervention on the axillary lymph nodes, because this procedure may carry the risk of arm swelling (lymphedema). In patients with a confirmed diagnosis of Stage 0 (DCIS), since the cancer cells have not yet spread beyond the ducts, the likelihood of lymph node involvement is almost zero. Therefore, touching the axillary lymph nodes or performing sampling (sentinel lymph node biopsy) is not standard practice in routine DCIS surgery. Avoiding unnecessary surgery is important for preserving the patient’s quality of life.
However, there are always exceptions in medicine. In certain special cases, even if the diagnosis is DCIS, we may need to identify and sample the sentinel lymph node during surgery. The main reason is the possibility that the final pathology report may unexpectedly reveal “a small focus of invasive cancer.” If the patient is undergoing a mastectomy (removal of the entire breast) and the lymph node has not been sampled during the operation, it may later become technically very difficult or impossible to access that area again. Therefore, this procedure is added to surgery for safety in patients scheduled for mastectomy.
Situations requiring lymph node biopsy in Stage 0 disease include:
- Planned mastectomy
- Presence of a palpable breast mass
- Very large tumor diameter
- High-grade tumor structure
Is Breast-Conserving Surgery Safe for Early Stage (Stage 1 and 2A)?
Stage 1 and Stage 2A constitute the group of “early-stage invasive breast cancer.” At this stage, tumors are generally small, and there is either no lymph node involvement or only very limited involvement. The question our patients ask most frequently during outpatient visits is: “Doctor, wouldn’t my chances of survival be higher if the entire breast were removed?” This is a very common belief in society, but it is not scientifically accurate.
Numerous scientific studies and decades of patient follow-up have demonstrated a clear fact: in early-stage breast cancer, there is no difference in patient survival between breast-conserving surgery (provided it is followed by radiation therapy) and removal of the entire breast. In other words, preserving the breast does not increase cancer risk or mean incomplete treatment. Both methods are equally safe from an oncological perspective.
The choice depends on the patient’s personal preferences and medical suitability. Breast-conserving surgery is a smaller procedure, recovery is much faster, and it preserves body integrity. However, patients who choose this method must accept a radiotherapy course lasting 3 to 6 weeks after surgery. Mastectomy, on the other hand, is a larger operation but generally eliminates the need for radiotherapy.
The factors influencing the decision-making process are:
- Location of the tumor within the breast
- Volume of the breast tissue
- Expectation regarding cosmetic outcome
- Access to radiotherapy
- Genetic risk factors
How Are Axillary Lymph Nodes Evaluated in Early-Stage Breast Cancer?
In early-stage invasive breast cancer, determining whether cancer cells have spread to the axilla is of vital importance for the course of treatment, even if the tumor is small. In the past, all axillary lymph nodes were removed for this evaluation, leading to severe arm swelling and restricted movement. In modern surgery, however, this approach has completely changed. Today, a much more precise and tissue-preserving method called Sentinel Lymph Node Biopsy (SLNB) is applied as the gold standard.
The principle of this procedure is quite simple: lymphatic drainage from the breast does not occur randomly but follows a specific pattern. The first destination of a cancer cell leaving the tumor is the “sentinel” lymph node. During surgery, we identify this first station using special dyes or tracers and remove only this node (or these nodes). While the surgery continues, the pathologist examines the node. If the sentinel node is free of cancer, there is no need to remove the dozens of remaining axillary lymph nodes. This protects the axilla from unnecessary surgical trauma.
The advantages of sentinel lymph node biopsy are:
- Less pain
- Faster recovery
- Reduced risk of arm swelling
- Lower risk of nerve injury
- Prevention of movement restriction

Prof. Dr. Ebru Ayvazoğlu Soy is a physician known for her academic background and surgical experience in the field of general surgery. After graduating from TED Ankara College in 1998, she completed her medical education at Hacettepe University Faculty of Medicine in 2005. She completed her residency training in the Department of General Surgery at Başkent University Faculty of Medicine in 2012, obtained the title of Associate Professor in 2019, and became a Professor in 2024. She currently serves as a faculty member in the Department of General Surgery at Ankara Medipol University Faculty of Medicine. With nearly 100 publications in international indexed journals and numerous scientific presentations, Prof. Dr. Ayvazoğlu Soy is a member of the International College of Surgeons, The Transplantation Society, Turkish Surgical Association and the Ankara Surgical Association. In addition to her academic position at Ankara Medipol University, she also sees patients in her private clinic in Çankaya, specializing in general surgery, breast surgery, and endocrine surgery.

